JP2014503500A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503500A5 JP2014503500A5 JP2013540062A JP2013540062A JP2014503500A5 JP 2014503500 A5 JP2014503500 A5 JP 2014503500A5 JP 2013540062 A JP2013540062 A JP 2013540062A JP 2013540062 A JP2013540062 A JP 2013540062A JP 2014503500 A5 JP2014503500 A5 JP 2014503500A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- hypoxia
- ldh
- group
- ldh5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 22
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 206010021143 Hypoxia Diseases 0.000 claims 16
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims 15
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims 15
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 claims 13
- 230000007954 hypoxia Effects 0.000 claims 13
- 230000000694 effects Effects 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 10
- 108010029485 Protein Isoforms Proteins 0.000 claims 8
- 102000001708 Protein Isoforms Human genes 0.000 claims 8
- MWTUOSWPJOUADP-XDJHFCHBSA-N (5z)-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-(1-methylindol-5-yl)-1,2,4-triazolidin-3-one Chemical compound O=C1C=C(O)C(C(C)C)=C\C1=C\1N(C=2C=C3C=CN(C)C3=CC=2)C(=O)NN/1 MWTUOSWPJOUADP-XDJHFCHBSA-N 0.000 claims 6
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims 6
- 229960003005 axitinib Drugs 0.000 claims 6
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 6
- 229960000397 bevacizumab Drugs 0.000 claims 6
- 229960002412 cediranib Drugs 0.000 claims 6
- 229950004161 ganetespib Drugs 0.000 claims 6
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 claims 5
- 102100031357 L-lactate dehydrogenase C chain Human genes 0.000 claims 5
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 5
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 5
- 101150050566 LDHC gene Proteins 0.000 claims 5
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 5
- 229950006418 dactolisib Drugs 0.000 claims 5
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims 5
- 238000001514 detection method Methods 0.000 claims 5
- 229960001433 erlotinib Drugs 0.000 claims 5
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 5
- 101150035055 ldh3 gene Proteins 0.000 claims 5
- 229960000639 pazopanib Drugs 0.000 claims 5
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 5
- 229960000235 temsirolimus Drugs 0.000 claims 5
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 5
- 229950000578 vatalanib Drugs 0.000 claims 5
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 5
- 101001090713 Homo sapiens L-lactate dehydrogenase A chain Proteins 0.000 claims 4
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102400000011 Cytochrome b-c1 complex subunit 9 Human genes 0.000 claims 2
- 101800000778 Cytochrome b-c1 complex subunit 9 Proteins 0.000 claims 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 101001051207 Homo sapiens L-lactate dehydrogenase B chain Proteins 0.000 claims 2
- 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 claims 2
- 102000004207 Neuropilin-1 Human genes 0.000 claims 2
- 108090000772 Neuropilin-1 Proteins 0.000 claims 2
- 102000052812 Ornithine decarboxylases Human genes 0.000 claims 2
- 108700005126 Ornithine decarboxylases Proteins 0.000 claims 2
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 2
- 108091006296 SLC2A1 Proteins 0.000 claims 2
- 108091006299 SLC2A2 Proteins 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 230000001146 hypoxic effect Effects 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 230000001023 pro-angiogenic effect Effects 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- WVWOOAYQYLJEFD-UHFFFAOYSA-N 1-(2-nitroimidazol-1-yl)-3-piperidin-1-ylpropan-2-ol Chemical compound C1=CN=C([N+]([O-])=O)N1CC(O)CN1CCCCC1 WVWOOAYQYLJEFD-UHFFFAOYSA-N 0.000 claims 1
- 102100030907 Aryl hydrocarbon receptor nuclear translocator Human genes 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000793115 Homo sapiens Aryl hydrocarbon receptor nuclear translocator Proteins 0.000 claims 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- -1 LDH4 Proteins 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000015021 Meningeal Neoplasms Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims 1
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000003567 ascitic fluid Anatomy 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 206010006007 bone sarcoma Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 210000000416 exudates and transudate Anatomy 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 208000021622 familial nonmedullary thyroid carcinoma Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 201000008822 gestational choriocarcinoma Diseases 0.000 claims 1
- 208000002409 gliosarcoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 230000009033 hematopoietic malignancy Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- 201000006866 hypopharynx cancer Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 101150095787 ldh2 gene Proteins 0.000 claims 1
- 101150100271 ldhb gene Proteins 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 201000005831 male reproductive organ cancer Diseases 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000022006 malignant tumor of meninges Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000003731 mucosal melanoma Diseases 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 201000006958 oropharynx cancer Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000007312 paraganglioma Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 208000028591 pheochromocytoma Diseases 0.000 claims 1
- 229950010456 pimonidazole Drugs 0.000 claims 1
- 201000002511 pituitary cancer Diseases 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000003804 salivary gland carcinoma Diseases 0.000 claims 1
- 206010039667 schwannoma Diseases 0.000 claims 1
- 210000001625 seminal vesicle Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 210000004872 soft tissue Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000004500 stellate cell Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 201000010653 vesiculitis Diseases 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41512710P | 2010-11-18 | 2010-11-18 | |
| US61/415,127 | 2010-11-18 | ||
| US201161510653P | 2011-07-22 | 2011-07-22 | |
| US201161510648P | 2011-07-22 | 2011-07-22 | |
| US201161510660P | 2011-07-22 | 2011-07-22 | |
| US61/510,648 | 2011-07-22 | ||
| US61/510,660 | 2011-07-22 | ||
| US61/510,653 | 2011-07-22 | ||
| PCT/US2011/061446 WO2012068487A1 (en) | 2010-11-18 | 2011-11-18 | Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014503500A JP2014503500A (ja) | 2014-02-13 |
| JP2014503500A5 true JP2014503500A5 (enExample) | 2015-01-15 |
Family
ID=45094281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013540062A Pending JP2014503500A (ja) | 2010-11-18 | 2011-11-18 | 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20140024030A1 (enExample) |
| EP (1) | EP2640384A1 (enExample) |
| JP (1) | JP2014503500A (enExample) |
| WO (1) | WO2012068487A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2653329C (en) | 2006-05-25 | 2018-01-16 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| EP2323737A2 (en) | 2008-08-08 | 2011-05-25 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| JP2014524469A (ja) * | 2011-08-19 | 2014-09-22 | シンタ ファーマシューティカルズ コーポレーション | 代謝拮抗剤とｈｓｐ９０阻害剤の組み合わせ癌療法 |
| JP2014532057A (ja) * | 2011-09-30 | 2014-12-04 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 粘表皮癌を治療する方法 |
| WO2013067162A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| JP2014534228A (ja) | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | 白金含有剤とｈｓｐ９０阻害剤の組合せ療法 |
| EP2780010A1 (en) | 2011-11-14 | 2014-09-24 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| WO2013170182A1 (en) * | 2012-05-11 | 2013-11-14 | Synta Pharmaceuticals Corp. | Treating cancer with an hsp90 inhibitory compound |
| JP2015525063A (ja) * | 2012-05-16 | 2015-09-03 | シンタ ファーマスーティカルズ コーポレーション | 低酸素状態に基づくｈｓｐ９０インヒビターでの治療のための被験者の予備選択 |
| MX375794B (es) * | 2014-04-24 | 2025-03-07 | Pfizer | Axitinib para usarse en el tratamiento de cáncer de células renales metastásico. |
| RS62713B1 (sr) | 2014-08-11 | 2022-01-31 | Acerta Pharma Bv | Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora |
| US20170224819A1 (en) | 2014-08-11 | 2017-08-10 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor |
| HRP20220738T1 (hr) | 2014-08-11 | 2022-08-19 | Acerta Pharma B.V. | Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1 |
| JP7108018B2 (ja) | 2017-04-17 | 2022-07-27 | イエール ユニバーシティ | 急性肺傷害を処置または予防する化合物、組成物および方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4250255A (en) | 1977-07-11 | 1981-02-10 | Eastman Kodak Company | Assay method for isoenzyme activity |
| US6242208B1 (en) | 1988-07-15 | 2001-06-05 | International Reagents Corporation | LDH1 assay |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| JP5004392B2 (ja) | 1999-12-22 | 2012-08-22 | スージェン， インク． | インドリノン化合物を用いてｃ−ｋｉｔチロシン蛋白質キナーゼ機能を調節する方法 |
| AR034118A1 (es) | 2000-02-15 | 2004-02-04 | Sugen Inc | Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2002092124A1 (en) * | 2001-05-11 | 2002-11-21 | Wyeth | Methods for diagnosing and treating ischemia and reperfusion injury and compositions thereof |
| JP2006524710A (ja) | 2003-04-25 | 2006-11-02 | ギリアード サイエンシーズ， インコーポレイテッド | キナーゼインヒビターホスホネート抱合体 |
| EP2298748B1 (en) | 2004-11-18 | 2016-07-20 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| SE530596C2 (sv) | 2006-10-13 | 2008-07-15 | Mathias Karlsson | Metod att fastställa syrebrist i blod från skalpen under förlossning |
| EP2099933A4 (en) | 2006-11-21 | 2010-03-24 | Beth Israel Hospital | HYPOXIA-ASSOCIATED GENES AND PROTEINS FOR THE TREATMENT AND DIAGNOSIS OF PREGNANCY-RELATED COMPLICATIONS |
| US20080318241A1 (en) * | 2007-06-18 | 2008-12-25 | The Regents Of The University Of Michigan | Methods and Systems for Detecting Antiangiogenesis |
| NZ600235A (en) * | 2008-01-25 | 2013-11-29 | Theranostics Lab | Methods and compositions for the assessment of drug response |
| SG177938A1 (en) * | 2008-03-26 | 2012-02-28 | Theranos Inc | Methods and systems for assessing clinical outcomes |
-
2011
- 2011-11-18 EP EP11791158.6A patent/EP2640384A1/en not_active Withdrawn
- 2011-11-18 JP JP2013540062A patent/JP2014503500A/ja active Pending
- 2011-11-18 WO PCT/US2011/061446 patent/WO2012068487A1/en not_active Ceased
-
2013
- 2013-05-16 US US13/895,709 patent/US20140024030A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503499A5 (enExample) | ||
| Yu et al. | PPARγ/NF‐κB and TGF‐β1/Smad pathway are involved in the anti‐fibrotic effects of levo‐tetrahydropalmatine on liver fibrosis | |
| Tian et al. | Autophagy inhibits oxidative stress and tumor suppressors to exert its dual effect on hepatocarcinogenesis | |
| Kinneer et al. | Design and preclinical evaluation of a novel B7-H4–directed antibody–drug conjugate, AZD8205, alone and in combination with the PARP1-selective inhibitor AZD5305 | |
| JP2013545759A5 (enExample) | ||
| Peng et al. | Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by Apatinib | |
| Caumanns et al. | Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma | |
| Marks et al. | Molecular genetics and targeted therapeutics in biliary tract carcinoma | |
| CN116635082A (zh) | 抗体-药物缀合物和atr抑制剂的组合 | |
| JPWO2020130125A1 (ja) | 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ | |
| Guo et al. | Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia | |
| Takano et al. | Pioglitazone, a ligand for peroxisome proliferator-activated receptor-γ acts as an inhibitor of colon cancer liver metastasis | |
| TW201839399A (zh) | 癌症治療 | |
| TW201023852A (en) | Cancer therapy | |
| TW202402290A (zh) | 癌症治療 | |
| MG Saez | Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer | |
| Chiacchiera et al. | Signal-dependent regulation of gene expression as a target for cancer treatment: inhibiting p38α in colorectal tumors | |
| US20240398767A1 (en) | Inhibitors of the mtdh-snd1 protein complex for cancer therapy | |
| JP2018528949A5 (enExample) | ||
| Wang et al. | Antitumor effects of a covalent cyclin-dependent kinase 7 inhibitor in colorectal cancer | |
| Elayapillai et al. | Oklahoma nitrone-007 is an effective anticancer therapeutic agent targeting inflammatory and immune metabolism pathways in endometrial cancer | |
| Pinheiro et al. | Targeting metabolic reprogramming as an anti-cancer strategy: aiming at monocarboxylate transporters | |
| Liao et al. | Hepatoma-derived growth factor promotes the resistance to anti-tumor effects of nordihydroguaiaretic acid in colorectal cancer cells | |
| EP3883561A1 (en) | Pharmaceutical methods | |
| Couderc et al. | Targeting the PI3K/mTOR pathway in murine endocrine cell lines: in vitro and in vivo effects on tumor cell growth |